Literature DB >> 12165484

Cutting edge: a murine, IL-12-independent pathway of IFN-gamma induction by gram-negative bacteria based on STAT4 activation by Type I IFN and IL-18 signaling.

Marina A Freudenberg1, Thomas Merlin, Christoph Kalis, Yolande Chvatchko, Hella Stübig, Chris Galanos.   

Abstract

IFN-alphabeta is a potent immunoregulatory cytokine involved in the defense against viral and bacterial infections. In this study, we describe an as yet undefined IFN-alphabeta-dependent pathway of IFN-gamma induction in mice. This pathway is based on a synergism of IFN-alphabeta and IL-18, and is independent of IL-12 signaling yet dependent on STAT4. In contradiction to current dogma, we show further that IFN-alphabeta alone induces tyrosine phosphorylation of STAT4 in murine splenocytes of different mouse strains. This pathway participates in the induction of IFN-gamma by Gram-negative bacteria and is therefore expected to play a role whenever IFN-alpha or IFN-beta and IL-18 are produced concomitantly during bacterial, viral, or other infections.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12165484     DOI: 10.4049/jimmunol.169.4.1665

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  45 in total

1.  MPYS is required for IFN response factor 3 activation and type I IFN production in the response of cultured phagocytes to bacterial second messengers cyclic-di-AMP and cyclic-di-GMP.

Authors:  Lei Jin; Krista K Hill; Holly Filak; Jennifer Mogan; Heather Knowles; Bicheng Zhang; Anne-Laure Perraud; John C Cambier; Laurel L Lenz
Journal:  J Immunol       Date:  2011-08-03       Impact factor: 5.422

2.  IFN-alpha is not sufficient to drive Th1 development due to lack of stable T-bet expression.

Authors:  Hilario J Ramos; Ann M Davis; Thaddeus C George; J David Farrar
Journal:  J Immunol       Date:  2007-09-15       Impact factor: 5.422

3.  Type I interferon signaling regulates the composition of inflammatory infiltrates upon infection with Listeria monocytogenes.

Authors:  Kristina L Brzoza-Lewis; J Jason Hoth; Elizabeth M Hiltbold
Journal:  Cell Immunol       Date:  2011-12-06       Impact factor: 4.868

4.  Cell-Specific Requirements for STAT Proteins and Type I IFN Receptor Signaling Discretely Regulate IL-24 and IL-10 Expression in NK Cells and Macrophages.

Authors:  Djeneba Dabitao; Christian M Hedrich; Fengying Wang; Vimvara Vacharathit; Jay H Bream
Journal:  J Immunol       Date:  2018-02-07       Impact factor: 5.422

5.  Mast cells elicit proinflammatory but not type I interferon responses upon activation of TLRs by bacteria.

Authors:  Nicole Dietrich; Manfred Rohde; Robert Geffers; Andrea Kröger; Hansjörg Hauser; Siegfried Weiss; Nelson O Gekara
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-26       Impact factor: 11.205

6.  Cholera toxin adjuvant promotes a balanced Th1/Th2/Th17 response independently of IL-12 and IL-17 by acting on Gsα in CD11b⁺ DCs.

Authors:  J Mattsson; K Schön; L Ekman; L Fahlén-Yrlid; U Yrlid; N Y Lycke
Journal:  Mucosal Immunol       Date:  2014-11-26       Impact factor: 7.313

Review 7.  The power of combinatorial immunology: IL-12 and IL-12-related dimeric cytokines in infectious diseases.

Authors:  Christoph Hölscher
Journal:  Med Microbiol Immunol       Date:  2003-06-27       Impact factor: 3.402

Review 8.  Type I interferon: friend or foe?

Authors:  Giorgio Trinchieri
Journal:  J Exp Med       Date:  2010-09-13       Impact factor: 14.307

9.  Failure to induce IFN-β production during Staphylococcus aureus infection contributes to pathogenicity.

Authors:  Amber Kaplan; Jun Ma; Pierre Kyme; Andrea J Wolf; Courtney A Becker; Ching Wen Tseng; George Y Liu; David M Underhill
Journal:  J Immunol       Date:  2012-09-24       Impact factor: 5.422

10.  Topical resiquimod protects against visceral infection with Leishmania infantum chagasi in mice.

Authors:  Noah Craft; Ron Birnbaum; Natalie Quanquin; Marie Crisel B Erfe; Cara Quant; Jacquelyn Haskell; Kevin W Bruhn
Journal:  Clin Vaccine Immunol       Date:  2014-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.